$CASIF Income Statement | Understand Stock

$CASIF

$0.15 +$0.00 (0.0%) Close

$CASIF Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Product sales
Sublicensing revenue from a related party
Lease income from a related party
Revenues
Costs of revenues
Gross Profit
Operating (expenses) income:
Research and development
General and administrative
Selling and marketing
Other operating income
Gain on disposal of long-lived assets
Foreign exchange gain (loss)
Impairment of intangible assets
Total operating expenses
Loss from operations
Non-operating (expense) income:
Interest income, net
Interest expense
Interest income
Total interest income, net
Other income
Change in fair value of investments
Gain from sale of an equity investment
Impairment loss of long-term investments

Loss before income tax benefit and share of net loss in an equity investee
Income tax benefit
Net loss before share of net loss in an equity investee
Share of net loss in an equity investee
Net loss
Foreign currency translation adjustment
Total comprehensive loss
Less: Comprehensive loss attributable to redeemable noncontrolling interest
Comprehensive loss attributable to ordinary shareholders
Less:Loss attributable to redeemable noncontrolling interest
Accretion to redeemable noncontrolling interest redemption value
Deemed dividends to Wuxi LP
Net loss attributable to CASI Pharmaceuticals, Inc.
Net loss per share (basic) (in $ per share)
Net loss per share (diluted) (in $ per share)
Weighted average number of ordinary shares outstanding (basic)
Weighted average number of ordinary stock outstanding (diluted)

Comments